This week in therapeutics




Licensing status

Publication and contact information

Infectious disease

Fungal infection

IL-12; natural killer p30 receptor (NKp30; NCR3; CD337)

Patient and cell culture studies suggest IL-12 can increase NKp30 expression and enhance anticryptococcal immunity. In patients with HIV/AIDS, NKp30 expression was lower than that in healthy individuals. In NK cells from HIV-infected individuals, IL-12 stimulated NKp30 expression and anticryptococcal activity. Next steps include identifying the fungal ligand for NKp30 and elucidating downstream pathways.
OncoSec Medical Inc. has a DNA plasmid coding IL-12 in Phase II testing to treat various cancers.
Profectus BioSciences Inc. has DNA-encoded IL-12 in Phase I testing to treat HIV/AIDS.
Intrexon Corp. also has DNA-encoded IL-12 in Phase II or earlier testing to treat various cancers.

SciBX 6(45); doi:10.1038/scibx.2013.1294
Published online Nov. 21, 2013

Patent filed; available for licensing or partnership via Innovate Calgary at the University of Calgary

Li, S.S. et al. Cell Host Microbe; published online Oct. 16, 2013;
Contact: Christopher H. Mody, University of Calgary, Calgary, Alberta, Canada